Compare GSK plc (GSK) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs State Street PDR S&P Retail ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while State Street PDR S&P Retail ETF trades at $83.61 (market cap $389.66M). The key difference: GSK plc is far larger — about 235.8× State Street PDR S&P Retail ETF's market cap, and GSK plc pays a 3.9% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| GSK | XRT | |
|---|---|---|
Market Cap | $91.88B | $389.66M |
Volume | 7,730,529 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $92.35 |
52-Week Low | $43.24 | $77.28 |
Typical Hold Time | 93 Days | 44 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
XRT (SPDR S&P Retail ETF) trades at $83.45, up 0.65% with a bullish technical signal despite bearish moving averages. The ETF faces mixed sentiment as retail sales show volatility, with August's 1.2% rebound contrasting July's 0.6% decline. Key resistance sits at $85, while RSI-6 at 84.45 indicates potential overbought conditions. Recent news highlights holiday sales projections exceeding $1 trillion but concerns over consumer spending shifts toward value-oriented purchases.
Outlook remains cautious amid macroeconomic pressures; higher interest rates and inflation weigh on consumer sentiment, with analysts expecting continued underperformance versus broader markets. The ETF's equal-weight approach provides diversification, but selective consumer spending patterns and oil price volatility pose near-term risks. Investment appeal hinges on holiday season performance and Federal Reserve policy direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
